Table VII. Comparison of efficacies among neoadjuvant chemotherapy regimens.

Pts: Patients; N+: lymph-node metastasis; MFT: median follow up time; pCR: pathological complete response; pR: pathological response; LR: local recurrence; DM: distant metastasis; Bmab: bevazizumab; Ra: middle rectum; Rb: lower rectum, N/A: not applicable; DFS: disease-free survival; RFS: recurrence-free survival. *Tumor affected area over two-third. **Tumor regression grading (TRG) of 0 or 1, which was evaluated semiquantitatively on a scale of 0 to 3 (complete to poor response, respectively) according to National Comprehensive Cancer Network guidelines (28).